Appendix 4C & Commentary
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Landmark Research on Excess Cortisol & Alzheimers Disease
- US Patent Granted-Further Extends Xanamem Protection
- US FDA Feedback Enhances Alzheimers Study
- Launch of XanADu Phase II Clinical Trial
- Appendix 4D & Half Year Report
Later from Actinogen Medical
- Announcement of non-renounceable rights issue
- Further results in bio-ethanol test program
- New Patents Allowed for B-HSD1 Inhibitor
- R&D Tax Rebate
- FDA Feedback on Xanamem Alzheimers Trail
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical